Sponsored by
This paper summarizes the four clinical trials and the expanded access programs for Onc-201 in recurrent diffuse midline glioma. Onc-201 has a new brand name - it is now called dordaviprone. When used by itself, about 40% of the patients had the tumors stable or shrink, with a median survival of about 13.7 months from the time of starting Onc-201. There was no control group, but the median survival for this tumor type is only 12 months from diagnosis. These patients all had recurrent disease and were on average 10.9 months from diagnosis when starting Onc-201. Bottom line is these results are good, possibly the best ever reported so far in this disease, but of course not good enough. We need to get this drug approved so it can be used in creative combinations to improve these numbers.